4DMedical (ASX:4DX): A 78% One-Year Gain Sharpens Focus on Clinical Adoption

Aditi Sarkar

12 September 2026 01:45 AM AEST

4DMedical (ASX:4DX): A 78% One-Year Gain Sharpens Focus on Clinical Adoption

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

4DMedical Limited closed at AUD 3.36 on 11 September 2026 after a 78% one-year rise.
The latest session finished down AUD 0.12, or 3.45%, with Market Capitalisation recorded at about AUD 2bn.
The company’s operating model requires investors to separate Business execution from market-price movements.
Upcoming financial, operational and regulatory disclosures will provide the clearest evidence of progress.

A 78% rise over 12 months has placed 4DMedical Limited (ASX:4DX) in a different market position from a year earlier. The shares closed at AUD 3.36 on 11 September 2026, down AUD 0.12, or 3.45%, valuing the company at approximately AUD 2bn. The one-year figure is a factual reference and is not attributed to any announcement or event. The more durable assessment rests on the company's business model, execution priorities, financial capacity and the risks that could alter future outcomes.

Company Business

4DMedical develops software-based lung imaging and analysis products. Its portfolio includes CT:VQ for non-contrast ventilation and perfusion imaging, CT Lung Volume Analysis, lung-density tools, pulmonary hypertension assessment and XV Lung Ventilation Analysis. The company uses imaging data to provide functional information intended to support clinical assessment. It operates in Australia and the United States and works with healthcare providers, research institutions and other participants in the imaging pathway. Commercial progress depends on regulatory clearances, clinical use, reimbursement, integration into radiology workflows and recurring scan volumes.

Sector Context

Medical-imaging software sits between device regulation, hospital procurement and clinical practice. A regulatory clearance permits a product to be marketed for specified uses, but it does not guarantee adoption or reimbursement. Clinicians require evidence that a tool adds useful information, fits existing workflows and supports patient management. Hospitals also consider implementation cost, training, interoperability and payment mechanisms. 4DMedical's products analyse standard imaging inputs to generate additional functional information. The company's August 2026 announcement of Australian regulatory approval for CT:VQ broadened its addressable setting, while commercial execution still depends on customers using the product consistently.

Risks to Consider

Healthcare technology can face slow procurement and implementation cycles. Regulatory requirements differ by product and jurisdiction, and future changes may add cost or restrict claims. Clinical evidence may not lead to routine use if payers do not reimburse scans or providers find workflow integration difficult. Revenue concentration, customer trials and uneven scan volumes can make growth variable. Software performance, cybersecurity, data privacy and quality systems require ongoing investment. The company may need further capital if commercial receipts do not cover research, regulatory and operating expenditure. Competing imaging methods and established diagnostic pathways may limit adoption.

What to Watch Next

The most useful indicators are contracted sites, installations, reimbursement coverage and scan volumes rather than announcements of access alone. Investors can monitor the conversion of pilots into routine clinical use, average revenue per scan and the time required to implement new customers. Regulatory milestones remain important for individual products and regions. Evidence presented in clinical studies should be read for study design, patient numbers and endpoints. Partnerships can accelerate distribution, but their economic value depends on binding terms and utilisation. Cash receipts, operating expenditure and available funding will show whether commercial progress is narrowing the gap to sustainability.

How to Read the Current Position

4DMedical has assembled a specialised respiratory-imaging portfolio and secured regulatory pathways for several products. The next stage is commercial: turning access into repeat clinical activity and revenue. The 78% one-year share-price rise and AUD 2bn market capitalisation record the valuation at 11 September 2026, while the shares closed at AUD 3.36 after the latest session. Those market figures do not establish clinical uptake. Adoption, reimbursement, workflow integration and cash conversion will provide clearer evidence of whether the technology is becoming embedded in healthcare practice.

FAQs

Q:What was the 4DMedical Limited closing price on 11 September 2026?

A:The shares closed at AUD 3.36, down AUD 0.12, or 3.45% for the session.

Q:How much had 4DX shares gained over one year?

A:The stock data records a 78% rise over the 12 months to 11 September 2026.

Q:What does the market capitalisation show?

A:It records an approximate equity value of AUD 2bn at the stated close, not a forecast of business performance.

Q:What should readers monitor next?

A:Company-specific operating delivery, financial results, capital requirements and formally announced milestones remain the main measures to follow.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.